Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Alok Srivastava, Savita Rangarajan, Kaan Kavakli, Robert Klamroth, Gili Kenet, Liane Khoo, Chur-Woo You, Weiqun Xu, Niel Malan, Laurent Frenzel, Catherine N. Bagot, Oleksandra Stasyshyn, Chia-Yau Chang, Stacey Poloskey, Shauna Andersson, Zhiying Qiu, Baisong Mei, Steven W. Pipe

Blood (2021) 138 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2021-155018

Published: 2021

Journal Articles

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Blood (2021) 138 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2021-146021

Published: 2021

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Victor S. Blanchette, FRCP, Laura Tiseo, BSc, CCRP, David Lillicrap, MD, Shannon Jackson, MD FRCPC, Massimo Morfini, MD, Vanessa Bouskill, MN, Manuel Carcao, Margaret L. Rand, PhD, Derek Stephens, MSc, Liane Khoo, MD, Ester Zapotocka, MD, Vladimir Komrska, MD, Jan Blatny, MD PhD

Blood (2018) 132 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2018-99-111024

Published: 2018

Journal Articles

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Rebecca Kruse-Jarres, Michael U. Callaghan, Stacy E. Croteau, MD, Victor Jimenez-Yuste, Liane Khoo, Ri Liesner, Tadashi Matsushita, Michael Recht, Guy Young, Tiffany Chang, Christophe Dhalluin, Yunming Mu, Jin Xu, Jenny Devenport, Richard H. Ko, Paul Solari, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 89.

https://doi.org/10.1182/blood.V130.Suppl_1.89.89

Published: 2017

Journal Articles

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Michael U. Callaghan, Claude Negrier, Guy Young, Liane Khoo, Johnny Mahlangu, Jerzy Windyga, Johannes Oldenburg, Jin Xu, Olivier Catalani, Elina Asikanius, Joanne I. Adamkewicz, Midori Shima, MDPhD

Blood (2017) 130 (Supplement 1): 3668.

https://doi.org/10.1182/blood.V130.Suppl_1.3668.3668

Published: 2017

Journal Articles

Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis

John Rasko, MBBS, PhD, Justin Wong, PhD, William Ritchie, PhD, Ebner Olivia, BSc, Selbach Matthias, PhD, Jason WH Wong, PhD, Yizhou Huang, BSc, Dadi Gao, BSc, Maria Gonzalez, MSc, Kinsha Baidya, BSc, Annora Theong, BSc, Teh-Liane Khoo, MBBS, Charles G Bailey, PhD, Jeff Holst, PhD

Blood (2012) 120 (21): 112.

https://doi.org/10.1182/blood.V120.21.112.112

Published: 2012

NARROW

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis

Email alerts

ASH Publications

American Society of Hematology

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)

Health-Related Quality of Life Following Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in the Phase 3 Trial GENEr8-1

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Use of Bypassing Agents Prior to and Post Bypassing Agent Dosing Guidance during Emicizumab Prophylaxis: Analyses from the HAVEN 1 Study

Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only